Stockscreener 앱 받기
4.41
0.00%
0.00
시간 외 거래:
4.45
0.04
+0.91%
전일 마감가:
$4.41
열려 있는:
$4.19
하루 거래량:
3.64M
Relative Volume:
1.39
시가총액:
$678.88M
수익:
$181.41M
순이익/손실:
$-59.56M
주가수익비율:
-10.50
EPS:
-0.42
순현금흐름:
$-38.83M
1주 성능:
-19.67%
1개월 성능:
+4.01%
6개월 성능:
+50.51%
1년 성능:
+116.18%
1일 변동 폭
$4.09
$4.58
1주일 범위
$4.09
$5.4999
52주 변동 폭
$1.69
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
4.41 | 678.88M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR
Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks
Xeris Announces Changes To Its Board Of Directors - MarketScreener
Xeris Biopharma reshuffles board, appoints new director - Investing.com
Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com Australia
Xeris Announces Changes to Its Board of Directors - Business Wire
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World
Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com Australia
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa
Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business
Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph
12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa
Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics - Stock Titan
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St
Xeris BiopharmaPossibly the best Pharma Stock - MSN
Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World
Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews
Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider
What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey
Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook - TipRanks
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
자본화:
|
볼륨(24시간):